Abstract
Injection of a low dose of haloperidol, that has no obvious behavioral effects in normal mice, produces akinesia, catalepsy, and sensory neglect in MPTP-treated mice. GM1 ganglioside treatment eliminates all of these behavioral impairments and also partially restores striatal dopamine content. These observations suggest that the MPTP-treated mouse may be a valuable model for studying mechanisms underlying parkinsonism and that administration of GM1 ganglioside may be an effective therapy.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
-
Animals
-
Antipsychotic Agents / pharmacology
-
Behavior, Animal / drug effects
-
Corpus Striatum / drug effects
-
Corpus Striatum / metabolism*
-
Corpus Striatum / physiopathology
-
Dopamine / metabolism*
-
G(M1) Ganglioside / therapeutic use*
-
Haloperidol / pharmacology*
-
Male
-
Mice
-
Movement Disorders / chemically induced
-
Movement Disorders / drug therapy*
-
Movement Disorders / metabolism
-
Pyridines / administration & dosage*
Substances
-
Antipsychotic Agents
-
Pyridines
-
G(M1) Ganglioside
-
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
-
Haloperidol
-
Dopamine